Davide Capodanno: Independent Investigators Lead the First Head to Head DOAC Comparison
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in NEJM:
“Finally published: the COBRRA trial, the first randomized head-to-head comparison of major DOACs – something the companies would never have done themselves, as a direct confrontation goes beyond their commercial interests.
This was driven by independent investigators.
The results somewhat support the idea of apixaban being the ‘safer’ DOAC.
That said, the list of study limitations is long, and for me, labeling something as ‘safe’ is not enough — after all, even placebo is ‘safe’ when it comes to bleeding.”
Ali Kamiar, Graduate Student Research Assistant Graduate Student, Research Assistant at University of Miami, Miller School of Medicine, reposted Davide Capodanno’s post on LinkedIn.
“Valuable independent evidence comparing major DOACs. Highlights the importance of critically evaluating both safety endpoints and study limitations when translating data into clinical practice.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 7, 2026, 12:28Thrombosis in Cancer Patients: Why It Happens and How We Treat It Today
-
Jun 7, 2026, 12:01Addressing Real-World Challenges in Thrombosis Care Through Case-Based Learning – Thrombosis Canada
-
Jun 7, 2026, 11:46Zehraan Ibni Akbar: Transforming Laboratory Data into Clinical Decisions Through Platelet Disorder Recognition
-
Jun 7, 2026, 11:31Alice Zerbinati: Y-90 Radioembolization Expands Curative Options for Advanced Hepatocellular Carcinoma
-
Jun 7, 2026, 09:26Filimon Dagnew Bezabih: SNMMI Honors 18F-GP1 PET Imaging for Innovation in Thrombosis Detection
-
Jun 7, 2026, 06:57Chandran Nadarajan: Targeted Endovascular Thrombolysis Offers Organ-Saving Benefits in Vascular Occlusions
-
Jun 7, 2026, 05:50Sayan Koley: Lupus Anticoagulant – A Key Marker in Thrombosis Risk Assessment
-
Jun 7, 2026, 05:45Nicolas Hubacz: Watching a Heart Build Its Network
-
Jun 7, 2026, 05:40New Evidence Highlights the Urgent Need for Gender-Inclusive Bleeding Disorders Research – EHC